Tuesday, June 7, 2016 Daily Archives

Lonza Announces 25th Approved Biotherapeutic Using the GS Gene Expression System™

Lonza, a global leader in biological development and manufacturing, announced today that with the approval of CSL Behring’s IDELVION® fusion protein for Hemophilia B Therapy, the overall number of approved biotherapeutics expressed using our GS Gene Expression System™ now totals 25 products. IDELVION® is the third GS expressed product approved in 2016. CSL Behring developed IDELVION® internally by taking advantage of our GS Licensing Program. They began their development work with a Research Evaluation Agreement using the materials and tools…